Targeting the individual cancer patient

Advances in Personalized Cancer Management

Volumn , Issue , 2011, Pages 9-28

  Baltogiannis, Georgios ^a   Katsios, Christos S ^b   Roukos, Dimitrios H ^a  

^a UNIVERSITY OF IOANNINA   (Greece)

^b UNIVERSITY HOSPITAL OF IOANNINA   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84920995453     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.2217/EBO.11.279     Document Type: Chapter

References (56)

1. Haber DA, Gray NS, Baselga J. The evolving war on cancer. Cell 145(1), 19-24 (2011).
2. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J. Clin. 61(2), 69-90 (2011).
3. Warner E. Clinical practice. Breast-cancer screening. N. Engl. J. Med. 365(11), 1025-1032 (2011).
4. Early breast cancer trialists' collaborative group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomized trials. Lancet 365, 1687-1717 (2005).
5. Weitzel JN, Blazer KR, Macdonald DJ, Culver JO, Offit K. Genetics, genomics, and cancer risk assessment: State of the art and future directions in the era of personalized medicine. CA Cancer J. Clin. doi:10.3322/ caac.20128 (2011) (Epub ahead of print).
6. Zoras O, Katsios CS, Roukos DH. Personalizing prophylactic surgery in cancer: current practice and future perspectives from new genome-wide association studies. Exp. Rev. Anticancer Ther. 11(6), 813-816 (2011).
7. Roukos DH. Trastuzumab and beyond: sequencing cancer genomes and predicting molecular networks. Pharmacogenom. J. 11(2), 81-92 (2011).
8. Roukos DH. Cancer genome explosion and systems biology: impact on surgical oncology? Ann. Surg. Oncol. 18(1), 12-15 (2011).
9. Feero WG, Guttmacher AE, Collins FS. Genomic medicine - an updated primer. N. Engl. J. Med. 362(21), 2001-2011 (2010).
10. Hamburg MA, Collins FS. The path to personalized medicine. N. Engl. J. Med. 363(4), 301-304 (2010).
11. Stratton MR, Rahman N. The emerging landscape of breast cancer susceptibility. Nat. Genet. 40(1), 17-22 (2008).
12. Politopoulos I, Gibson J, Tapper W, Ennis S, Eccles D, Collins A. Genome-wide association of breast cancer:composite likelihood with imputed genotypes. Eur. J. Hum. Genet. 19(2), 194-199 (2011).
13. Domchek SM, Friebel TM, Singer CF et al. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA 304(9), 967-975 (2010).
14. Narod SA, Offit K. Prevention and management of hereditary breast cancer. J. Clin. Oncol. 23(8), 1656-1663 (2005).
15. Collaborative group on hormonal factors in breast cancer: familial breast cancer:collaborative reanalysis of individual data from 52 epidemiological studies including 58,209 women with breast cancer and 101,986 women without the disease. Lancet 358(9291), 1389-1399 (2001).
16. Manolio TA, Collins FS, Cox NJ. Finding the missing heritability of complex diseases. Nature 461(7265), 747-753 (2009).
17. Wacholder S, Hartge P, Prentice R et al. Performance of common genetic variants in breast-cancer risk models. N. Engl. J. Med. 362(11), 986-993 (2010).
18. Travis RC, Reeves GK, Green J et al. Million women study collaborators: gene- environment interactions in 7610 women with breast cancer: prospective evidence from the million women study. Lancet 375(9732), 2143-2151 (2010).
19. Metcalfe KA, Finch A, Poll A et al. Breast cancer risks in women with a family history of breast or ovarian cancer who have tested negative for a BRCA1 or BRCA2 mutation. Br. J. Cancer. 100(2), 421-425 (2009).
20. Guilford P, Hopkins J, Harraway J et al. E-cadherin germline mutations in familial gastric cancer. Nature 392, 402-405 (1998).
21. Kaurah P, MacMillan A, Boyd N et al. Founder and recurrent CDH1 mutations in families with hereditary diffuse gastric cancer. JAMA 297, 2360-2372 (2007).
22. Roukos DH. Genome-wide association studies and aggressive surgery toward individualized prevention, and improved local control and overall survival for gastric cancer. Ann. Surg. Oncol. 16, 795-798 (2009).
23. Lynch HT, Kaurah P, Wirtzfeld D et al. Hereditary diffuse gastric cancer: diagnosis, genetic counseling, and prophylactic total gastrectomy. Cancer 112, 2655-2663 (2008).
24. Hebbard PC, Macmillan A, Huntsman D et al. Prophylactic total gastrectomy (PTG) for hereditary diffuse gastric cancer (HDGC): the newfoundland experience with 23 patients. Ann. Surg. Oncol. 16, 1890-1895 (2009).
25. Ziogas DE, Roukos DH. CDH1 testing: can it predict the prophylactic or therapeutic nature of total gastrectomy in hereditary diffuse gastric cancer? Ann. Surg. Oncol. 16(10), 2678-2681 (2009).
26. Lynch HT, Lynch PM, Lanspa SJ, Snyder CL, Lynch JF, Boland CR. Review of the Lynch syndrome: history, molecular genetics, screening, differential diagnosis, and medicolegal ramifications. Clin. Genet. 76(1), 1-18 (2009).
27. Guillem JG, Wood WC, Moley JF et al. ASCO; SSO: ASCO/SSO review of current role of riskreducing surgery in common hereditary cancer syndromes. J. Clin. Oncol. 24(28), 4642-4660 (2006).
28. Dulbecco R. A turning point in cancer research: sequencing the human genome. Science 231, 1055-1056 (1986).
29. Lander ES, Linton LM, Birren B et al. International human genome sequencing consortium: initial sequencing and analysis of the human genome. Nature 409, 860-921 (2001).
30. Venter JC, Adams MD, Myers EW et al. The sequence of the human genome. Science 291, 1304-1351 (2001).
31. [No author listed]: The human genome at ten. Nature 464(7289), 649-650 (2010).
32. Marshall E. Human genome 10th anniversary. Waiting for the revolution. Science 331(6017), 526-529 (2011).
33. Green ED, Guyer MS. National human genome research institute. Charting a course for genomic medicine from base pairs to bedside. Nature 470(7333), 204-213 (2011).
34. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 144(5), 646-674 (2011).
35. de Bono JS, Ashworth A. Translating cancer research into targeted therapeutics. Nature 467(7315), 543-549 (2010).
36. Flaherty KT, Puzanov I, Kim KB et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N. Engl. J. Med. 363, 809-819 (2010).
37. Chapman PB, Hauschild A, Robert C et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med. 364(26), 2507-2516 (2011).
38. Baselga J, Swain SM. Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat. Rev. Cancer 9(7), 463-475 (2009).
39. Gianni L, Dafni U, Gelber RD et al. Herceptin adjuvant (HERA) trial study tea. Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial. Lancet Oncol. 12(3), 236-244 (2011).
40. Perez EA, Romond EH, Suman VJ et al. Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2 - positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31. J. Clin. Oncol. 29(25), 3366-3373 (2011).
41. Maughan TS, Adams R, Smith CG et al. MRC COIN trial investigators: identification of potentially responsive subsets when cetuximab is added to oxaliplatin-fluoropyrimidine chemotherapy (CT) in firstline advanced colorectal cancer (aCRC): mature results of the MRC COIN trial. J. Clin. Oncol. 28(Suppl. 15), (2010) (Abstract 3502).
42. Maughan TS, Adams RA, Smith CG et al. MRC COIN trial investigators. Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer:results of the randomised Phase III MRC COIN trial. Lancet 377(9783), 2103-2114 (2011).
43. Pao W, Chmielecki J. Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer. Nat. Rev. Cancer 10(11), 760-774 (2010).
44. Keedy VL, Temin S, Somerfield MR et al. For the American society of clinical oncology provisional clinical opinion:Epidermal growth factor receptor (EGFR) mutation testing for patients with advanced non-small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy. J. Clin. Oncol. 29(15), 2121-2127 (2011).
45. Bhalla US, Iyengar R. Emergent properties of networks of biological signaling pathways. Science 283, 381-387 (1999).
46. Cutillas PR, Jørgensen C. Biological signalling activity measurements using mass spectrometry. Biochem. J. 434(2), 189-199 (2011).
47. Schlabach MR, Luo J, Solimini NL et al. Cancer proliferation gene discovery through functional genomics. Science 319, 620-624 (2008).
48. [No author listed]. Human genome: Genomes by the thousand. Nature 467, 1026-1027 (2010).
49. Wadman M. Fifty genome sequences reveal breast cancer's complexity. Nature doi:10.1038/news.2011.203 (2011) (Epub ahead of print).
50. Hudson TJ, Anderson W, Artez A et al. International network of cancer genome projects. Nature 464, 993-998 (2010).
51. Blaxter M. Genetics. Revealing the dark matter of the genome. Science 330(6012), 1758-1759 (2010).
52. Ashworth A, Lord CJ, Reis-Filho JS. Genetic interactions in cancer progression and treatment. Cell 145(1), 30-38 (2011).
53. Yoshida K, Miki Y. Role of BRCA1 and BRCA2 as regulators of DNA repair, transcription, and cell cycle in response to DNA damage. Cancer Sci. 95(11), 866-871 (2004).
54. Pharoah PD, Antoniou A, Bobrow M, Zimmern RL, Easton DF, Ponder BA. Polygenic susceptibility to breast cancer and implications for prevention. Nat. Genet. 31(1), 33-36 (2002).
55. Altshuler DM, Gibbs RA, Peltonen L et al. International hapmap 3 consortium:integrating common and rare genetic variation in diverse human populations. Nature 467(7311), 52-58 (2010).
56. Manolio TA. Genomewide association studies and assessment of the risk of disease. N. Engl. J. Med. 363(2), 166-176 (2010).